Replies to post #331637 on Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

That's why my only concern is to see Brilacidin in a covid trial. We need to see whether or not it works in humans as it does in vitro.

If we get a successful trial in covid the bidding wars should start shortly thereafter.

If not, we drop in price and wait to move another indication forward. But, we'll have the benefit of more knowing about Brilacidin at that time.






Message in reply to: the bolded section

"IPIX has already been recognized. So far they haven't wanted to pay what "B" is worth"

I think that is a fundamental misunderstanding of the way Business Development in Big Pharma (or even mid-sized Pharma) works.

If there was a real belief in BP that brilacidin was a serious contender for a knock out treatment for COVID-19 then there would be an enormous bidding war and no one would care whether the pps was 21 cents or $21 or more.

No company would sit on the side lines nickelling and diming in the hope of shaving a few tens or hundreds of millions off the offer price or from the deal structure because they know a competitor would snap it up.

The fact is that either BP is unaware of brilacidin (and I agree that this is unlikely) or they don't believe that the molecule is a serious contender when it gets to the clinic.

[leavetheguntakethecannolis]

Once human trails are completed and B is shown to be successful against CV19 your concerns about the viability of B will vanish into thin air.

Until that day occurs these “concerns” about viability will likely continue to be posted here regularly from various entities.

If you possess a “fundamental understanding of the way Business Development in Big Pharma” operates I’m sure you are aware of this.